Bio Green Med Solution Declares $0.15 Quarterly Preferred Dividend
Bio Green Med Solution, Inc., a fire safety equipment distributor, declared a $0.15 per share quarterly cash dividend on its 6% Convertible Exchangeable Preferred Stock. The dividend was paid February 1, 2026.
Bio Green Med Solution, Inc., a fire safety equipment distribution company, declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend was paid on February 1, 2026, to shareholders of record as of January 22, 2026. Read more dividend announcements.
The dividend announcement came as the company reported fourth quarter and full year 2025 financial results. The company did not disclose the ex-dividend date.
| Dividend Details | Information |
|---|---|
| Amount | $0.15 per share |
| Security | 6% Convertible Exchangeable Preferred Stock |
| Record Date | January 22, 2026 |
| Payment Date | February 1, 2026 |
| Frequency | Quarterly |
Recent Business Developments
Bio Green Med Solution shifted its business focus in 2025 following the acquisition of Fitters Sdn. Bhd., a fire safety materials and equipment company, on September 12, 2025. The company also sold its Plogosertib drug candidate to Tethra Biosciences Inc. for $300,000 plus a potential milestone payment of $170,000.
In November 2025, the company executed a warrant exchange agreement, issuing 1,402,605 shares of common stock to holders of warrants originally issued in June 2025.
Financial Performance
Cash and cash equivalents totaled $3.5 million as of December 31, 2025, compared to $3.8 million at year-end 2024. Net cash used in operating activities improved to $4.8 million for the twelve months ended December 31, 2025, from $8.0 million in the prior year period.
Product revenue from fire safety equipment sales reached $0.7 million for both the fourth quarter and full year 2025, following the Fitters acquisition. Cost of sales for the segment totaled $0.6 million for the year.
Research and development expenses dropped to $0.8 million for 2025 from $6.7 million in 2024, reflecting the company's exit from pharmaceutical development. CEO Datuk Dr. Doris Wong Sing EE said the Fitters acquisition and asset sales strengthened the company's balance sheet.
The company estimates its current cash resources will fund operations through the third quarter of 2026.